Resolving Binding Events on the Multifunctional Human Serum Albumin

Overview

Journal ChemMedChem

Specialties Chemistry
Pharmacology

Date 2020 Mar 13

PMID 32162429

Citations 9

Authors

Lea Wenskowsky

Michael Wagner

Johannes Reusch

Herman Schreuder

Hans Matter

Till Opatz

Stefan Matthias Petry

Affiliations

Soon will be listed here.

Abstract

Physiological processes rely on initial recognition events between cellular components and other molecules or modalities. Biomolecules can have multiple sites or mode of interaction with other molecular entities, so that a resolution of the individual binding events in terms of spatial localization as well as association and dissociation kinetics is required for a meaningful description. Here we describe a trichromatic fluorescent binding- and displacement assay for simultaneous monitoring of three individual binding sites in the important transporter and binding protein human serum albumin. Independent investigations of binding events by X-ray crystallography and time-resolved dynamics measurements (switchSENSE technology) confirm the validity of the assay, the localization of binding sites and furthermore reveal conformational changes associated with ligand binding. The described assay system allows for the detailed characterization of albumin-binding drugs and is therefore well-suited for prediction of drug-drug and drug-food interactions. Moreover, conformational changes, usually associated with binding events, can also be analyzed.

Citing Articles

Research on the Interaction Mechanism and Structural Changes in Human Serum Albumin with Hispidin Using Spectroscopy and Molecular Docking.

Fan S, Wang W, Zhou Y, Gao X, Zhang Q, Zhang M Molecules. 2024; 29(3).

PMID: 38338399 PMC: 10856618. DOI: 10.3390/molecules29030655.

NMR and Docking Calculations Reveal Novel Atomistic Selectivity of a Synthetic High-Affinity Free Fatty Acid vs. Free Fatty Acids in Sudlow's Drug Binding Sites in Human Serum Albumin.

Venianakis T, Primikyri A, Opatz T, Petry S, Papamokos G, Gerothanassis I Molecules. 2023; 28(24).

PMID: 38138481 PMC: 10745614. DOI: 10.3390/molecules28247991.

Molecular Basis for the Selectivity of DHA and EPA in Sudlow's Drug Binding Sites in Human Serum Albumin with the Combined Use of NMR and Docking Calculations.

Alexandri E, Venianakis T, Primikyri A, Papamokos G, Gerothanassis I Molecules. 2023; 28(9).

PMID: 37175134 PMC: 10180286. DOI: 10.3390/molecules28093724.

Enlarging the Stokes Shift by Weakening the π-Conjugation of Cyanines for High Signal-to-Noise Ratiometric Imaging.

Yue Y, Zhao T, Xu Z, Chi W, Chai X, Ai J Adv Sci (Weinh). 2022; 10(3):e2205080.

PMID: 36424136 PMC: 9875656. DOI: 10.1002/advs.202205080.

Multivalent binding kinetics resolved by fluorescence proximity sensing.

Schulte C, Solda A, Spanig S, Adams N, Bekic I, Streicher W Commun Biol. 2022; 5(1):1070.

PMID: 36207490 PMC: 9546861. DOI: 10.1038/s42003-022-03997-3.

References

van Witteloostuijn S, Pedersen S, Jensen K . Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation. ChemMedChem. 2016; 11(22):2474-2495. DOI: 10.1002/cmdc.201600374. View

Halgren T . Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 2009; 49(2):377-89. DOI: 10.1021/ci800324m. View

Kontermann R . Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009; 23(2):93-109. DOI: 10.2165/00063030-200923020-00003. View

Petitpas I, Grune T, Bhattacharya A, Curry S . Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol. 2001; 314(5):955-60. DOI: 10.1006/jmbi.2000.5208. View

Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen U, Ribel U . Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995; 312 ( Pt 3):725-31. PMC: 1136174. DOI: 10.1042/bj3120725. View

Ryan A, Chung C, Curry S . Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin. BMC Struct Biol. 2011; 11:18. PMC: 3104944. DOI: 10.1186/1472-6807-11-18. View

Langer A, Hampel P, Kaiser W, Knezevic J, Welte T, Villa V . Protein analysis by time-resolved measurements with an electro-switchable DNA chip. Nat Commun. 2013; 4:2099. PMC: 3719012. DOI: 10.1038/ncomms3099. View

Er J, Vendrell M, Tang M, Zhai D, Chang Y . Fluorescent dye cocktail for multiplex drug-site mapping on human serum albumin. ACS Comb Sci. 2013; 15(9):452-7. DOI: 10.1021/co400060b. View

Jameson L, Smith N, Annunziata O, Dzyuba S . Interaction of BODIPY dyes with bovine serum albumin: a case study on the aggregation of a click-BODIPY dye. Phys Chem Chem Phys. 2016; 18(21):14182-5. PMC: 4908817. DOI: 10.1039/c6cp00420b. View

10.

Kontermann R . Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011; 22(6):868-76. DOI: 10.1016/j.copbio.2011.06.012. View

11.

Sudlow G, Birkett D, Wade D . Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976; 12(6):1052-61. View

12.

Koehler M, Zobel K, Beresini M, Caris L, Combs D, Paasch B . Albumin affinity tags increase peptide half-life in vivo. Bioorg Med Chem Lett. 2002; 12(20):2883-6. DOI: 10.1016/s0960-894x(02)00610-8. View

13.

Wenskowsky L, Schreuder H, Derdau V, Matter H, Volkmar J, Nazare M . Identification and Characterization of a Single High-Affinity Fatty Acid Binding Site in Human Serum Albumin. Angew Chem Int Ed Engl. 2017; 57(4):1044-1048. DOI: 10.1002/anie.201710437. View

14.

Bech E, Pedersen S, Jensen K . Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives. ACS Med Chem Lett. 2018; 9(7):577-580. PMC: 6047018. DOI: 10.1021/acsmedchemlett.8b00226. View

15.

Spector A, Santos E, Ashbrook J, Fletcher J . Influence of free fatty acid concentration on drug binding to plasma albumin. Ann N Y Acad Sci. 1973; 226:247-58. DOI: 10.1111/j.1749-6632.1973.tb20486.x. View

16.

Bhattacharya A, Grune T, Curry S . Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol. 2000; 303(5):721-32. DOI: 10.1006/jmbi.2000.4158. View

17.

Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P . Human serum albumin: from bench to bedside. Mol Aspects Med. 2012; 33(3):209-90. DOI: 10.1016/j.mam.2011.12.002. View

18.

Ryan A, Ghuman J, Zunszain P, Chung C, Curry S . Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. J Struct Biol. 2010; 174(1):84-91. PMC: 3073228. DOI: 10.1016/j.jsb.2010.10.004. View

19.

Kober A, Sjoholm I . The binding sites on human serum albumin for some nonsteroidal antiinflammatory drugs. Mol Pharmacol. 1980; 18(3):421-6. View

20.

Curry S . Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet. 2009; 24(4):342-57. DOI: 10.2133/dmpk.24.342. View